Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04405245 · ClinicalTrials.gov registry record · Phase 2
Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma
A Phase 2 study of Ocular Hypertension and Primary Open Angle Glaucoma, sponsored by EyePoint Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 194
- Enrollment target
- 20
- Study locations
NCT04405245 is a Phase 2 study of Ocular Hypertension and Primary Open Angle Glaucoma that has completed, run by EyePoint Pharmaceuticals. The registered enrollment target is 194 participants, below the 275-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (29% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT04405245, a Phase 2 study of Ocular Hypertension and Primary Open Angle Glaucoma, has completed, sponsored by EyePoint Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 194 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a phase 2, double masked, randomized, multi-center, parallel-group, 28-day study assessing the safety, tolerability and ocular hypotensive efficacy of AKB-9778 Ophthalmic Solution 4.0% administered once (AM) or twice (AM \& PM) daily when used as an adjunctive therapy to latanoprost ophthalmic solution 0.005% once daily (PM) in subjects with elevated IOP due to OAG or OHT.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Latanoprost ophthalmic solution
- DRUG AKB-9778 4%
Study Locations (20)
California
- United Medical Research Institute - Inglewood
- North Valley Eye Medical Group - Mission Hills
- Eye Research Foundation - Newport Beach
- North Bay Eye Associates - Petaluma
Georgia
- Clayton Eye Clinical Research, LLC - Morrow
- Coastal Research Associates - Roswell
Kansas
- Kannarr Eye Care - Pittsburg
- Heart of America Eye Care, P.A. - Shawnee Mission
North Carolina
- Charlotte Eye, Ear, Nose & Throat Assoc. (CEENTA) - Charlotte
- James D. Branch, MD Ophthalmology - Winston-Salem
Ohio
- Apex Eye - Cincinnati
- Abrams Eye Center - Cleveland
Pennsylvania
- Scott & Christie and Assoc - Cranberry Township
- Eye Care Specialists - Kingston
Tennessee
- Total Eye Care - Memphis
- Advancing Vision Research - Nashville
Florida
- Shettle Eye Research - Largo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 194 participants |
| Start Date | 2020-06-06 |
| Est. Completion | 2020-11-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04405245
The ClinicalTrials.gov registry entry for NCT04405245 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 194 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 275-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (29% lower). The listed sponsor is EyePoint Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Ocular Hypertension appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT04405245 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Georgia, Kansas.
Frequently Asked Questions
What is clinical trial NCT04405245 about?
NCT04405245 is a clinical study titled "Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma". This is a phase 2, double masked, randomized, multi-center, parallel-group, 28-day study assessing the safety, tolerability and ocular hypotensive efficacy of AKB-9778 Ophthalmic Solution 4.0% administered once (AM) or twice (AM \& PM) daily when used as an adjunctive therapy to latanoprost ophthalm...
What is the current status of trial NCT04405245?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 194 participants. The study started on 2020-06-06. Estimated completion is 2020-11-05.
What conditions does trial NCT04405245 study?
This clinical trial studies the following conditions: Ocular Hypertension, Primary Open Angle Glaucoma.
What interventions are being tested in trial NCT04405245?
The interventions under investigation include: Placebo (DRUG), Latanoprost ophthalmic solution (DRUG), AKB-9778 4% (DRUG).
Who is sponsoring clinical trial NCT04405245?
This trial is sponsored by EyePoint Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04405245 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Kansas, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ocular Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension
RECRUITING · Phase 2
-
Travoprost Five Day Posology Study
COMPLETED · Phase 2
-
Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma
COMPLETED · Phase 2
-
Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma
COMPLETED · Phase 2
-
A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension
COMPLETED · Phase 2
-
Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.